In addition, CCR7 is recognized as a therapeutic target in hematologic malignancies, such as T-cell prolymphocytic leukemia [26], B-cell chronic lymphocytic leukemia [27], and non-Hodgkin's lymphoma [28]. Here, CCR7 is linked to T-cell prolymphocytic leukemia.